Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Agenus

Biotech & Life Sciences · Lexington, United States · Founded 1994 · IPO 2000 Thoroughbred

Our goal is to treat cancers with novel combinations using our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines & adjuvants

Valuation
$203M
Market cap · May/2026
Revenue
$114M
Latest reported FY

Investors

6 investors on Agenus's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage
Advent Life Sciences
Mentor Capital
Flagship Pioneering
EW Healthcare Partners
Grazia Equity
BCM Ventures

Global footprint

Where Agenus has talent and traffic

Workforce by country
9 countries with
team presence
🇺🇸 United States84.7%
🇬🇧 United Kingdom11.1%
🇻🇳 Vietnam0.7%
🇨🇱 Chile0.7%
🇶🇦 Qatar0.7%
Top 5 of 9 shown
Web traffic by country
9.1K monthly visits
across markets
🇺🇸 United States50.5%
🇮🇳 India28.6%
🇬🇧 United Kingdom12.1%
🇮🇩 Indonesia3.3%
🇫🇷 France2.2%
Top 5 markets shown

Market sentiment

What the market is saying about Agenus

An AI-synthesized read of the highest-engagement posts about Agenus on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Agenus on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.